Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acrivon Therapeutics Inc (ACRV)

Acrivon Therapeutics Inc (ACRV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,785
  • Shares Outstanding, K 31,555
  • Annual Sales, $ 0 K
  • Annual Income, $ -80,560 K
  • EBIT $ -89 M
  • EBITDA $ -92 M
  • 60-Month Beta 1.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.49
  • Number of Estimates 4
  • High Estimate -0.46
  • Low Estimate -0.52
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +18.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.78 +33.14%
on 11/07/25
2.55 -7.06%
on 12/04/25
+0.34 (+16.75%)
since 11/05/25
3-Month
1.35 +75.56%
on 09/08/25
2.67 -11.24%
on 09/08/25
+1.04 (+78.20%)
since 09/05/25
52-Week
1.05 +125.71%
on 06/02/25
8.00 -70.38%
on 02/05/25
-4.07 (-63.20%)
since 12/05/24

Most Recent Stories

More News
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial...

ACRV : 2.37 (-1.66%)
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine development Favorable ACR-2316 preclinical...

ACRV : 2.37 (-1.66%)
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing...

ACRV : 2.37 (-1.66%)
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316...

ACRV : 2.37 (-1.66%)
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

ACRV : 2.37 (-1.66%)
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

ACRV : 2.37 (-1.66%)
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

ACRV : 2.37 (-1.66%)
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

ACRV : 2.37 (-1.66%)
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

ACRV : 2.37 (-1.66%)
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer

ACRV : 2.37 (-1.66%)

Business Summary

Acrivon Therapeutics Inc. is a clinical stage biopharmaceutical company developing precision oncology medicines which matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon's proprietary proteomics-based patient responder identification platform,...

See More

Key Turning Points

3rd Resistance Point 2.57
2nd Resistance Point 2.51
1st Resistance Point 2.44
Last Price 2.37
1st Support Level 2.30
2nd Support Level 2.24
3rd Support Level 2.17

See More

52-Week High 8.00
Fibonacci 61.8% 5.35
Fibonacci 50% 4.53
Fibonacci 38.2% 3.70
Last Price 2.37
52-Week Low 1.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar